Innovative Cell Therapy, Omisirge, Receives FDA Approval to Reduce Infection Risk in Blood Cancer Treatments
The FDA has approved Omisirge (omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to speed up the recovery of neutrophils and reduce infection risk. Omisirge is intended for use in adults and pediatric patients aged 12 and older with blood cancers who are undergoing umbilical cord blood transplantation after a myeloablative conditioning regimen. Blood […]